SCHEMBL14718858

SCHEMBL14718858

CS(=O)(=O)c1ccc2nccc(Nc3ccc(O)cc3)c2c1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 9/20 0.72
KDR P35968 3/20 0.72
RET P07949 2/20 0.72
MAPK14 Q16539 2/20 0.72
PKMYT1 Q99640 1/20 0.72
GAK O14976 1/20 0.64
MAPKAPK2 P49137 2/20 0.60
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
ATM Q13315 1/20 0.52
RIPK1 Q13546 2/20 0.51
RIPK3 Q9Y572 1/20 0.50
TGFBR1 P36897 3/20 0.48
KCNH2 Q12809 3/20 0.47
RAF1 P04049 1/20 0.47
BRAF P15056 1/20 0.47
MAP4K4 O95819 1/20 0.46
PDE4B Q07343 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2589187 0.87 RIPK2 (0.69) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2596055 0.87 RIPK2 (0.69) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2595061 0.87 RIPK2 (0.68) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2595031 0.85 RIPK2 (0.70) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2588253 0.85 RIPK2 (0.67) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2595095 0.84 RIPK2 (0.65) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2594833 0.84 RIPK2 (0.65) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2595969 0.84 RIPK2 (0.65) RIPK2KDRRETMAPK14PKMYT1
SCHEMBL2595104 0.84 RIPK2 (0.65) RIPK2KDRRETMAPK14PKMYT1
Gw559768X SCHEMBL2592805 0.84 RIPK2 (1.00) RIPK2KDRRETMAPK14PKMYT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP claimed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US claimed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 US disclosed
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 EP disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885KDR 404/4885RET 193/4885
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885KDR 404/4885RET 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.